MNOV vs MREO

MediciNova, Inc. vs Mereo BioPharma Group plc — Valuation Comparison 2026

MNOV

Biotechnology
MediciNova, Inc.
Quality
6.2
out of 10
Value Trap
45
WARN
Price
$1.37
Last close
Models
9/13
Active
VS

MREO

Biotechnology
Mereo BioPharma Group plc
Quality
5.0
out of 10
Value Trap
12
SAFE
Price
$0.34
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType MNOV Fair ValueMNOV Upside MREO Fair ValueMREO Upside
Bayesian DCF Intrinsic $0.67 -51.1% $0.17 -50.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.33 -3.2% $0.85 +146.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MNOV vs MREO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MNOV vs MREO — Which Stock Is More Undervalued?

MNOV scores higher with a 6.2/10 quality rating vs MREO's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MediciNova, Inc. (MNOV) and Mereo BioPharma Group plc (MREO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MNOV currently trades at $1.37 with a QOC of 6.2/10, while MREO trades at $0.34 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).